Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

A short-term in vivo model for giant cell tumor of bone

Authors: Maurice Balke, Anna Neumann, Károly Szuhai, Konstantin Agelopoulos, Christian August, Georg Gosheger, Pancras CW Hogendoorn, Nick Athanasou, Horst Buerger, Martin Hagedorn

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Because of the lack of suitable in vivo models of giant cell tumor of bone (GCT), little is known about its underlying fundamental pro-tumoral events, such as tumor growth, invasion, angiogenesis and metastasis. There is no existing cell line that contains all the cell and tissue tumor components of GCT and thus in vitro testing of anti-tumor agents on GCT is not possible. In this study we have characterized a new method of growing a GCT tumor on a chick chorio-allantoic membrane (CAM) for this purpose.

Methods

Fresh tumor tissue was obtained from 10 patients and homogenized. The suspension was grafted onto the CAM at day 10 of development. The growth process was monitored by daily observation and photo documentation using in vivo biomicroscopy. After 6 days, samples were fixed and further analyzed using standard histology (hematoxylin and eosin stains), Ki67 staining and fluorescence in situ hybridization (FISH).

Results

The suspension of all 10 patients formed solid tumors when grafted on the CAM. In vivo microscopy and standard histology revealed a rich vascularization of the tumors. The tumors were composed of the typical components of GCT, including (CD51+/CD68+) multinucleated giant cells whichwere generally less numerous and contained fewer nuclei than in the original tumors. Ki67 staining revealed a very low proliferation rate. The FISH demonstrated that the tumors were composed of human cells interspersed with chick-derived capillaries.

Conclusions

A reliable protocol for grafting of human GCT onto the chick chorio-allantoic membrane is established. This is the first in vivo model for giant cell tumors of bone which opens new perspectives to study this disease and to test new therapeutical agents.
Appendix
Available only for authorised users
Literature
1.
Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, Hardes J, Gosheger G: Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008, 134: 969-978. 10.1007/s00432-008-0370-x.CrossRefPubMed
2.
Campanacci M, Baldini N, Boriani S, Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am. 1987, 69: 106-114.PubMed
3.
Freyschmidt J, Ostertag H, Jundt G: Knochentumoren. 2. Auflage. Berlin, Heidelberg, New York, Tokio, Springer. 1998, 611-649.
4.
Carrasco CH, Murray JA: Giant cell tumors. Orthop Clin North Am. 1989, 20: 395-405.PubMed
5.
Salzer-Kuntschik M: [Differential diagnosis of giant cell tumor of bone]. Verh Dtsch Ges Pathol. 1998, 82: 154-159.PubMed
6.
Campanacci M: Bone and Soft Tissue Tumors. New York: Springer. 1990, 117-151.
7.
Larsson SE, Lorentzon R, Boquist L: Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish Cancer Registry for the years 1958 through 1968. J Bone Joint Surg Am. 1975, 57: 167-173.PubMed
8.
Schwartz HS: Update on giant cell tumor of bone. Compr Ther. 1998, 24: 488-493.PubMed
9.
Enneking WF: A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986, 9-24.
10.
Masui F, Ushigome S, Fujii K: Giant cell tumor of bone: a clinicopathologic study of prognostic factors. Pathol Int. 1998, 48: 723-729. 10.1111/j.1440-1827.1998.tb03973.x.CrossRefPubMed
11.
Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, Moreau G, Davis AM: Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res. 2002, 248-258.
12.
Lausten GS, Jensen PK, Schiodt T, Lund B: Local recurrences in giant cell tumour of bone. Long-term follow up of 31 cases. Int Orthop. 1996, 20: 172-176. 10.1007/s002640050057.CrossRefPubMed
13.
Moskovszky L, Szuhai K, Krenacs T, Hogendoorn PC, Szendroi M, Benassi MS, Kopper L, Fule T, Sapi Z: Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes Chromosomes Cancer. 2009, 48: 468-479. 10.1002/gcc.20656.CrossRefPubMed
14.
15.
Wulling M, Engels C, Jesse N, Werner M, Delling G, Kaiser E: The nature of giant cell tumor of bone. J Cancer Res Clin Oncol. 2001, 127: 467-474. 10.1007/s004320100234.CrossRefPubMed
16.
Lindeman JH, Hanemaaijer R, Mulder A, Dijkstra PD, Szuhai K, Bromme D, Verheijen JH, Hogendoorn PC: Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol. 2004, 165: 593-600. 10.1016/S0002-9440(10)63323-8.CrossRefPubMedPubMedCentral
17.
Forsyth RG, De Boeck G, Baelde JJ, Taminiau AH, Uyttendaele D, Roels H, Praet MM, Hogendoorn PC: CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone. J Bone Miner Res. 2009, 24: 70-77. 10.1359/jbmr.080905.CrossRefPubMed
18.
Forsyth RG, De Boeck G, Bekaert S, De Meyer T, Taminiau AH, Uyttendaele D, Roels H, Praet MM, Hogendoorn PC: Telomere biology in giant cell tumour of bone. J Pathol. 2008, 214: 555-563. 10.1002/path.2301.CrossRefPubMed
19.
Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS: Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am. 1999, 81: 811-820.CrossRefPubMed
20.
Malek F, Krueger P, Hatmi ZN, Malayeri AA, Faezipour H, O'Donnell RJ: Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop. 2006, 30: 495-498. 10.1007/s00264-006-0146-3.CrossRefPubMedPubMedCentral
21.
Rock MG, Pritchard DJ, Unni KK: Metastases from histologically benign giant-cell tumor of bone. J Bone Joint Surg Am. 1984, 66: 269-274.PubMed
22.
Siebenrock KA, Unni KK, Rock MG: Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up. J Bone Joint Surg Br. 1998, 80: 43-47. 10.1302/0301-620X.80B1.7875.CrossRefPubMed
23.
Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M, Mercuri M: Histologically verified lung metastases in benign giant cell tumours-14 cases from a single institution. Int Orthop. 2006, 30: 499-504. 10.1007/s00264-006-0204-x.CrossRefPubMedPubMedCentral
24.
Cheng JC, Johnston JO: Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases. Clin Orthop Relat Res. 1997, 205-214.
25.
Sakkers RJ, van der Heul RO, Kroon HM, Taminiau AH, Hogendoorn PC: Late malignant transformation of a benign giant-cell tumor of bone. A case report. J Bone Joint Surg Am. 1997, 79: 259-262.PubMed
26.
Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM: Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int. 2004, 75: 71-77.CrossRefPubMed
27.
Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF: Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone. 2008, 42: 68-73. 10.1016/j.bone.2007.08.038.CrossRefPubMed
28.
Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, et al: Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010
29.
DeFouw DO, Rizzo VJ, Steinfeld R, Feinberg RN: Mapping of the microcirculation in the chick chorioallantoic membrane during normal angiogenesis. Microvasc Res. 1989, 38: 136-147. 10.1016/0026-2862(89)90022-8.CrossRefPubMed
30.
Rahn H, Paganelli CV, Ar A: The avian egg: air-cell gas tension, metabolism and incubation time. Respir Physiol. 1974, 22: 297-309. 10.1016/0034-5687(74)90079-6.CrossRefPubMed
31.
Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A, Bikfalvi A: Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci USA. 2005, 102: 1643-1648. 10.1073/pnas.0408622102.CrossRefPubMedPubMedCentral
32.
Dumartin L, Quemener C, Laklai H, Herbert J, Bicknell R, Bousquet C, Pyronnet S, Castronovo V, Schilling MK, Bikfalvi A, Hagedorn M: Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology. 138: 1595-1606. 1606 e1591-1598
33.
Balke M, Neumann A, Kersting C, Agelopoulos K, Gebert C, Gosheger G, Burger H, Hagedorn M: Morphologic characterization of osteosarcoma growth on the chick chorioallantoic membrane. BMC Res Notes. 2010, 3: 58-10.1186/1756-0500-3-58.CrossRefPubMedPubMedCentral
34.
Smits AM, van Laake LW, den Ouden K, Schreurs C, Szuhai K, van Echteld CJ, Mummery CL, Doevendans PA, Goumans MJ: Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium. Cardiovasc Res. 2009, 83: 527-535. 10.1093/cvr/cvp146.CrossRefPubMed
35.
Pajor L, Szuhai K, Mehes G, Kosztolanyi G, Jakso P, Lendvai G, Szanyi I, Kajtar P: Combined metaphase, interphase cytogenetic, and flow cytometric analysis of DNA content of pediatric acute lymphoblastic leukemia. Cytometry. 1998, 34: 87-94. 10.1002/(SICI)1097-0320(19980415)34:2<87::AID-CYTO5>3.0.CO;2-9.CrossRefPubMed
36.
Rossi S, Szuhai K, Ijszenga M, Tanke HJ, Zanatta L, Sciot R, Fletcher CD, Dei Tos AP, Hogendoorn PC: EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res. 2007, 13: 7322-7328. 10.1158/1078-0432.CCR-07-1744.CrossRefPubMed
37.
Szuhai K, Bezrookove V, Wiegant J, Vrolijk J, Dirks RW, Rosenberg C, Raap AK, Tanke HJ: Simultaneous molecular karyotyping and mapping of viral DNA integration sites by 25-color COBRA-FISH. Genes Chromosomes Cancer. 2000, 28: 92-97. 10.1002/(SICI)1098-2264(200005)28:1<92::AID-GCC11>3.0.CO;2-2.CrossRefPubMed
38.
Athanasou NA, Quinn J: Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol. 1990, 43: 997-1003. 10.1136/jcp.43.12.997.CrossRefPubMedPubMedCentral
39.
Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N: Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol. 2005, 36: 945-954. 10.1016/j.humpath.2005.07.005.CrossRefPubMed
40.
Balke M, Ahrens H, Streitbuerger A, Koehler G, Winkelmann W, Gosheger G, Hardes J: Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol. 2008, 135: 149-158.CrossRefPubMed
41.
Ghert MA, Rizzo M, Harrelson JM, Scully SP: Giant-cell tumor of the appendicular skeleton. Clin Orthop Relat Res. 2002, 201-210.
42.
Kito M, Moriya H, Mikata A, Harigaya K, Takenouchi T, Takada N, Tatezaki S, Umeda T: Establishment of a cell line from a human giant cell tumor of bone. Clin Orthop Relat Res. 1993, 353-360.
43.
Oreffo RO, Marshall GJ, Kirchen M, Garcia C, Gallwitz WE, Chavez J, Mundy GR, Bonewald LF: Characterization of a cell line derived from a human giant cell tumor that stimulates osteoclastic bone resorption. Clin Orthop Relat Res. 1993, 229-241.
44.
Hagedorn M, Balke M, Schmidt A, Bloch W, Kurz H, Javerzat S, Rousseau B, Wilting J, Bikfalvi A: VEGF coordinates interaction of pericytes and endothelial cells during vasculogenesis and experimental angiogenesis. Dev Dyn. 2004, 230: 23-33. 10.1002/dvdy.20020.CrossRefPubMed
45.
Hagedorn M, Wilting J: Chick chorioallantoic membrane assay: growth factor and tumor-induced angiogenesis and lymphangiogenesis. 2004, Berlin, Heidelberg, Germany: Springer
46.
Kunzi-Rapp K, Genze F, Kufer R, Reich E, Hautmann RE, Gschwend JE: Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. J Urol. 2001, 166: 1502-1507. 10.1016/S0022-5347(05)65820-X.CrossRefPubMed
47.
MacDonald IC, Schmidt EE, Morris VL, Chambers AF, Groom AC: Intravital videomicroscopy of the chorioallantoic microcirculation: a model system for studying metastasis. Microvasc Res. 1992, 44: 185-199. 10.1016/0026-2862(92)90079-5.CrossRefPubMed
48.
Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA, Papagiannakopoulos T, Quigley JP: Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res. 2005, 65: 10959-10969. 10.1158/0008-5472.CAN-05-2228.CrossRefPubMed
49.
Tsuchiya Y, Endo Y, Sato H, Okada Y, Mai M, Sasaki T, Seiki M: Expression of type-IV collagenases in human tumor cell lines that can form liver colonies in chick embryos. Int J Cancer. 1994, 56: 46-51.CrossRefPubMed
50.
Denko NC, Giaccia AJ: Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res. 2001, 61: 795-798.PubMed
51.
Alberghini M, Kliskey K, Krenacs T, Picci P, Kindblom L, Forsyth R, Athanasou NA: Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch. 2010, 456: 97-103. 10.1007/s00428-009-0863-2.CrossRefPubMed
52.
Almog N, Henke V, Flores L, Hlatky L, Kung AL, Wright RD, Berger R, Hutchinson L, Naumov GN, Bender E, et al: Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. Faseb J. 2006, 20: 947-949. 10.1096/fj.05-3946fje.CrossRefPubMed
53.
Ma WW, Adjei AA: Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009, 59: 111-137. 10.3322/caac.20003.CrossRefPubMed
54.
Russell WMS, Burch RL: The Principles of Humane Experimental Technique. 1992, Potters Bar, UK: Universities Federation for Animal Welfare (UFAW), New edition
55.
Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R, Hogendoorn P, Kroep J, Wass J, Athanasou N: Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer. 2010, 10: 462-10.1186/1471-2407-10-462.CrossRefPubMedPubMedCentral
Metadata
Title
A short-term in vivo model for giant cell tumor of bone
Authors
Maurice Balke
Anna Neumann
Károly Szuhai
Konstantin Agelopoulos
Christian August
Georg Gosheger
Pancras CW Hogendoorn
Nick Athanasou
Horst Buerger
Martin Hagedorn
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-241

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Glioblastoma-derived Leptin Induces Tube Formation and Growth of Endothelial Cells: Comparison with VEGF Effects

Research article

Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY

Research article

Activating mutation in MET oncogene in familial colorectal cancer

Research article

Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection

Research article

Gain of DNA methylation is enhanced in the absence of CTCF at the human retinoblastoma gene promoter

Study protocol

Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux®and particle therapy]
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits